These include Keynote-024 and Keynote-042, which demonstrated the superiority of first-line pembrolizumab monotherapy vs. platinum-based chemotherapy in PDL-1 ≥ 50 and PDL-1 ≥ 1 NSCLC patients, respectively. The gene discussed is CD274; the disease is non-small cell lung carcinoma.